|
The Vanguard Group, Inc. ( IRSH)
Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc
23-Jun-2021 / 14:54 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
|
Name of person dealing (Note 1)
|
The Vanguard Group, Inc.
|
|
Company dealt in
|
Xeris Pharmaceuticals, Inc.
|
|
Class of relevant security to which the dealings being disclosed relate (Note 2)
|
$0.001 Common Stock
|
|
Date of dealing
|
21 June 2021
|
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long
|
Short
|
|
|
Numbers
|
(%)
|
Numbers
|
(%)
|
|
(1) Relevant securities
|
3,167,622
|
4.77%
|
|
|
|
(2) Derivatives (other than options)
|
|
|
|
(3) Options and agreements to purchase/sell
|
|
|
|
Total
|
3,167,622
|
4.77%
|
|
|
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
|
Class of relevant security:
|
Long
|
Short
|
|
|
Numbers
|
(%)
|
Numbers
|
(%)
|
|
(1) Relevant securities
|
|
|
|
|
|
(2) Derivatives (other than options)
|
|
|
|
(3) Options and agreements to purchase/sell
|
|
|
|
Total
|
|
|
|
|
Ap20
1. Dealings (Note 4)
(a) Purchases and sales
|
Purchase/sale
|
Number of relevant securities
|
Price per unit (Note 5)
|
|
Purchase
|
38,720
|
3.95 USD
|
|
Sale
|
1,406
|
3.95 USD
|
(b) Derivatives transactions (other than options transactions)
|
Product name,
e.g. CFD
|
Nature of transaction
(Note 6)
|
Number of relevant securities
(Note 7)
|
Price per unit
(Note 5)
|
|
Not Applicable
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product name,
e.g. call option
|
Writing, selling, purchasing, varying etc.
|
Number of securities to which the option relates (Note 7)
|
Exercise price
|
Type, e.g. American, European etc.
|
Expiry date
|
Option money paid/received per unit (Note 5)
|
|
Not Applicable
|
|
|
|
|
|
|
(ii) Exercising
|
Product name,
e.g. call option
|
Number of securities
|
Exercise price per unit (Note 5)
|
|
Not Applicable
|
|
|
(e) Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature of transaction
(Note 8)
|
Details
|
Price per unit
(if applicable) (Note 5)
|
|
Not Applicable
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
|
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
|
|
|
Is a Supplemental Form 8 attached? (Note 9) NO
|
Date of disclosure
|
23 June 2021
|
|
Contact name
|
Shawn Acker
|
|
Telephone number
|
001-610-669-8989
|
|
If a connected EFM, name of offeree/offeror with which connected
|
|
|
If a connected EFM, state nature of connection (Note 10)
|
|
|
